Strategic partnerships Leverage RedShiftBio’s established backing from Waters Corporation, Illumina Ventures, and Technology Venture Partners to pursue co-development, joint marketing, or distribution partnerships with biopharma manufacturers, contract development and manufacturing organizations (CDMOs), and instrument service providers to expand global reach.

Clinical manufacturing fit Position HaLCon as a critical bioprocess analytics tool for real-time protein titer measurement, targeting biopharmaceutical manufacturing teams seeking faster, cost-effective titer assays to streamline production, quality control, and batch release.

High-value platforms Highlight Aurora and Apollo systems’ ultra-sensitive MMS technology and lasers for detailed molecular structure analysis, aiming at R&D labs and early-stage biotechs focused on protein, mAb, RNA, and LNP characterization to enable faster discovery and optimization.

Global demo network Capitalize on the StructIR Lab presence and partner sites in the UK and Belgium to offer hands-on demonstrations, samples processing, and validated use cases, converting interest into trials and long-term deployments across regions.

Sales expansion signals Capitalize recent leadership additions and a growing sales organization by aligning targeted account plans with biopharma manufacturing and analytics leaders, driving outreach to key decision makers at major biopharma companies and CDMOs.